Postdoc in the @marsonlab@GladstoneInst/@UCSF. Parker Scholar @parkerici. Interested in genomics, CRISPR, cancer immunotherapy, and much more! 🇨🇦
Excited to share that the Arce Lab is launching today at @arcinstitute !
We will explore the mechanisms controlling immune cell function using genomics and biochemistry in an effort to understand immune-mediated diseases. arcinstitute.org/labs/arcela…
Excited to share the latest from the @MarsonLab! An investigation of context-specific gene regulation in T cells, which led to dynamic mechanisms required to control T cell rest and activation.
Published today in @Nature thanks to the work of many!
nature.com/articles/s41586-0…
Excited to share a milestone in our forward genetics developments! Today in @Nature we report massive mutagenesis screening in T cells with base editors, increasing resolution from genes to nucleotides nature.com/articles/s41586-0…
A @MarsonLab story with my dear friend @carlcward
1/10
I am very excited to share our paper on the interactions between #gdTcells and cancer cells, out today in @Nature! Using #CRISPR screens, we uncovered unexpected pathways in cancer cells regulating target molecules recognized by γδ T cells. @MarsonLab
1/2
nature.com/articles/s41586-0…
Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. rdcu.be/c7avS
Thrilled to share the first Eyquem lab paper! Today we report in @CellCellPress evolving the AAV6 capsid to enable efficient engineering of murine T cells. An exciting collab with @asokanduke and led by the brilliants @WilliamNyberg and Jon Ark
cell.com/cell/fulltext/S0092… 🧵1/11
I’m hiring a computational biologist at Genentech to analyze cutting-edge single-cell genomics and high-throughput screening data in an extremely collaborative environment focused on finding cures for disease. Please reach out to learn more.
careers.gene.com/us/en/job/G…
I'm very excited to share our review article rdcu.be/cHLHy@NatRevImmunol where we discussed how IL-2 has been engineered since its discovery to improve its in vivo activity and T cell selectivity and drive therapeutic efficacy in the context of autoimmunity and cancer.